Who Gets Hired, and Which Side of the Company They Join
Nabla Bio's LinkedIn page lists 26 named employees inside a Cambridge, Massachusetts biotech headquartered at 840 Memorial Drive, with an 11–50 headcount band and 10,953 followers. The company's own job board, on the other hand, advertises a New York office for an SRE/Backend Engineer and a Technical Product Manager — EHR, plus U.S.-remote roles for a Growth Marketing Director, Partnership Director, and Mid-Market Account Executive, and a Finance Analyst internship in Paris. Both pictures are real. They describe two recruitment surfaces running under one legal entity.
The biotech surface is the easier one to read. Nabla Bio launched in 2021 as a spin-out of George Church's lab at Harvard, where co-founder and CEO Surge Biswas completed his PhD and developed the first protein language models. LinkedIn's data shows the company has since raised $37 million from backers including Radical Ventures, Khosla Ventures, and Zetta Venture Partners (CB Insights puts total raised at $37.39M). Its own postings name "molecular biology and protein engineering" backgrounds explicitly, alongside machine learning talent. The platform is JAM-2, a multimodal generative modeling system the team announced in 2025; the integrated wet lab has executed "dozens of programs across the industry," per company posts. The narrower hiring message that recurs across Nabla Bio's LinkedIn is a search for "problem solvers who think from first principles, thrive in fast-paced environments, and want to make a big impact," paired with an internal value of "steep growth over static titles," language that fits a biotech with LinkedIn-reported headcount in the dozens.
The second surface is harder to read but impossible to ignore. The board's six most recent postings are not antibody roles; they are SRE, EHR product management, growth marketing, partnerships, mid-market sales, and finance. The address lines say "New York office" and "Anywhere in the United States," not Cambridge, not "fully in-person." Nabla Bio's own homepage says the technical team is "fully in person and based in Cambridge, MA," so the New York and remote roles almost certainly sit in a commercial, clinical-platform, or enterprise-software function the company is building alongside the wet-lab platform. The MyVisaJobs record, which lists Machine Learning Engineer as the most common H-1B position, fits a Cambridge-headquartered technical core that files immigration sponsorship in Boston, alongside a separate commercial layer with U.S.-remote or New York hires. The EHR Product Manager role is a signal in its own right: electronic-health-record integration work only makes sense if Nabla Bio is shipping a clinical-facing product surface, not just selling antibody designs to pharma partners. The pharma partners that Nabla Bio's LinkedIn page names explicitly are AstraZeneca, Bristol Myers Squibb, and Takeda.
What this means for candidates is that "Nabla Bio" maps to two recruiting funnels, and which one you apply to depends on which problem you want to spend the next few years on. Protein engineers, molecular biologists, and ML researchers join the Cambridge wet-lab platform team, where the work is bench-close and the posted pace is five programs in six weeks, end-to-end in-house. Engineers, product managers, marketers, sales leaders, and finance hires join a separate commercial or clinical-product layer that recruits nationally and into New York. The brand says it is "designing antibodies with atomic precision." The board says it is also wiring that science into the systems pharma and clinicians actually use.
What the Roles Pay
Nabla Bio is small enough that almost every compensation figure attached to it comes from a handful of postings, not a salary survey. The clearest numbers come from the company's own listings. On Zero G Talent's board, a Site Reliability Engineer / Backend Engineer in Nabla Bio's New York office is posted at $160,000–$220,000 per year, while a Technical Product Manager — EHR role in the same office carries a band of $140,000–$180,000. Remote-eligible commercial roles sit lower: a Growth Marketing Director anywhere in the United States is listed at $140,000–$180,000, a Partnership Director at $120,000–$160,000, and a Mid-Market Account Executive at $90,000–$120,000. A Finance Analyst internship is also listed in the Paris office, though the posting does not publish a specific figure. The board's compiled band across the five salaried listings runs from $102,000 to $204,000 with a median around $180,000.
| Role | Location | Posted band |
|---|---|---|
| SRE / Backend Engineer | New York | $160,000–$220,000 |
| Technical Product Manager — EHR | New York | $140,000–$180,000 |
| Growth Marketing Director | Anywhere in the U.S. | $140,000–$180,000 |
| Partnership Director | Anywhere in the U.S. | $120,000–$160,000 |
| Mid-Market Account Executive | Anywhere in the U.S. | $90,000–$120,000 |
Those numbers describe a Cambridge-based biotech that Salary.com's company overview describes as employing somewhere between 6 and 10 people in the $0M–$1M revenue range. The narrow headcount explains a quirk of the salary data worth flagging: third-party estimates can swing by tens of thousands of dollars depending on which role the site latched onto. Salary.com pegs the highest-paying Nabla Bio job as a Head of Data Science at $263,675 annually, based on its compensation dataset. That figure is not contradicted by anything in Nabla Bio's postings; it sits above the highest band on the board, but it also reflects a single inferred role rather than a confirmed employee. Glassdoor carries anonymous submissions for only three jobs at "Nabla," which is too thin to anchor a band on its own.
Equity at this stage of Nabla Bio's life works differently than at a public pharma company. The company is privately held, and shares change hands through a private secondary marketplace. Forge, one platform that handles private company transfers, notes that any Nabla Bio transaction requires company approval and runs through "any transfer restrictions or right of first refusal (ROFR) processes Nabla Bio may have in place". A grant is real, but the path to liquidity runs through the company's blessing first.
The benefits picture is consistent with a small biotech that wants to compete for senior hires. Nabla Bio's careers page frames the work as demanding and the mission (designing and delivering molecules that may one day reach patients) as the upside, but the actual package is also concrete. Salary.com summarizes it as a package "designed to support your health, financial future, and overall well-being," and lists competitive pay alongside recurring equity reviews. Country-specific benefits vary by employee location. The Nabla Bio careers site does not publish a line-item benefits sheet, so a candidate should expect the standard U.S. biotech mix (health coverage, retirement contributions, and equity) without a published dollar value attached to any of it.
The honest read: at Nabla Bio today, base salary is published precisely because the role is open, equity terms exist but require direct conversation to pin down, and the benefits story is "comparable to peer biotechs" rather than "documented here." Ask the recruiter for the grant size in dollars at offer, the vesting schedule in writing, and whether any ROFR applies before you sign.
How the Hiring Loop Runs
Nabla Bio's hiring loop runs longer than most biotech startups of its size. Glassdoor's dataset puts the average process at 41 days across six candidate submissions, a timeline more typical of late-stage clinical companies than a Series A platform lab founded in 2021. 39% of job seekers rate their interview at Nabla as positive, and the average difficulty score lands at 3 out of 5, with technical roles like full-stack development drawing the hardest reviews and operational roles like customer success rated the easiest. The implication is real: this is not a place where a polished resume and a confident phone screen will carry you. Expect a multi-stage gauntlet weighted toward demonstrating that you can do the work, not just talk about it.
The pipeline begins with a recruiter screen, the standard first gatekeeper. Nabla Bio's own job posts make clear what passes that filter. For computational biology roles, the company wants evidence of a multi-month research project that produced a publication or a tool impactful enough to be used by a previous employer, lab, or external users. For antibody engineering positions, the bar is a PhD or equivalent in molecular biology, cell biology, biochemistry, or a related field, plus a track record of designing and optimizing yeast display screening campaigns. Recruiters are scanning for credentials that signal you can contribute on day one to the developability pipeline: characterizing antibodies for affinity, cross-reactivity, stability, polyspecificity, aggregation, and hydrophobicity.
Candidates who clear the recruiter move into technical rounds. Across Glassdoor's Nabla submissions, one verified Paris-based candidate reported a LeetCode-style sequence following an initial screening: one easy exercise followed by one medium-difficulty problem. That data point is from a single submission, so it shouldn't be treated as universal, but it matches the pattern of platform-stage biotech companies that screen rigorously for coding fluency even in scientific roles. Wet-lab candidates should expect equivalent rigor on assay design, statistical interpretation of screening data, and experimental troubleshooting.
After technical evaluation, the loop typically closes with a culture and motivation interview. Nabla Bio states on its careers page that its work is "demanding," driven by "problems rather than prestige," and that team members work "side by side, with focus and urgency." Interviewers are listening for whether candidates actually find that appealing, or whether they're coming from a slower-moving academic environment where publication cadence, not molecule throughput, defines success.
What separates candidates who advance? Three patterns surface across the research. First, project ownership matters more than years of experience: Nabla Bio's own posts repeatedly frame roles around scaling pipelines and solving hard design problems, language that rewards people who can point to concrete deliverables. Second, technical communication is non-negotiable, even for scientists: the STAR-format problem-solving interview remains standard, and vague storytelling about "contributing to" projects tends to fall flat when interviewers ask what specifically you built, ran, or decided. Third, the company expects genuine interest in its mission; the "Get in touch" closing on Nabla Bio's careers page and its repeated emphasis on scientific standards suggest that candidates who can articulate why programmable therapeutics, why now, and why at Nabla Bio specifically will land differently than those who treat the loop as generic biotech shopping.
One caveat worth flagging: the Glassdoor sample for Nabla Bio is small (six submissions for process length, fewer for role-specific difficulty), so the 41-day average and difficulty rankings are directional rather than definitive. Candidates should plan for a 5–7 week process and treat any single data point (including the Paris LeetCode report) as one signal among many.
Candidates interested in current openings can review the live Nabla Bio roles on Zero G Talent to see which positions are actively recruiting and how the descriptions map to the hiring bar described above.
Where the Work Happens
Nabla Bio runs a single, fully in-person operation out of Cambridge, Massachusetts, with its headquarters at 840 Memorial Drive in the Riverside Technology Center. The company states this plainly on both its website and LinkedIn: "Team: Fully in-person and based in Cambridge, MA." There is no remote option advertised, no hybrid schedule, and no satellite offices on the company's own materials, a notable position in an industry where many AI-focused biotechs have embraced distributed workforces.
That policy flows directly from how Nabla Bio builds its product. The company describes itself as combining "de novo drug design with large-scale, human-relevant testing" inside one integrated dry/wet-lab engine. Antibody candidates generated by JAM-2, the company's flagship generative protein design model, are handed off to an in-house wet lab for binding assays, developability profiling, and functional testing. In a 2026 announcement, Nabla Bio reported designing, building, and testing five programs in one parallelized campaign "end-to-end in-house in ~6 weeks." That turnaround depends on scientists and engineers sitting in the same building, moving sequences from GPU cluster to bench to plate reader without handoff delays. A distributed team would break that loop.
The lab footprint sits inside Cambridge's biotech cluster, a deliberate geography. Cambridge places Nabla Bio within walking distance of Harvard, MIT, the Broad Institute, and a deep contractor network for protein production and cryo-EM work, relevant because the company has reported ångström-level agreement between Cryo-EM structures and JAM-2's de novo designs. CEO Surge Biswas completed his PhD there, and the company has historically drawn from that same talent pipeline. CB Insights ranks Nabla Bio as a Leader in its AI antibody design platforms market, alongside 8 other companies including Chai Discovery, Antiverse, and Protillion Biosciences; geographically those competitors are scattered, with Galux in Seoul, Antiverse in Cardiff, Scala Biodesign in Tel Aviv, LabGenius in London, Adimab in Lebanon, New Hampshire, and Xaira Therapeutics in South San Francisco. Nabla Bio's Cambridge address puts it in the densest concentration of computational biology talent in the United States.
On Zero G Talent's own job board, the picture complicates that single-building story. Recent postings include the SRE/Backend Engineer and Technical Product Manager – EHR roles in a New York office, alongside U.S.-remote roles for a Growth Marketing Director, Partnership Director, and Mid-Market Account Executive, and an Internship – Finance Analyst listed under a Paris office. The Cambridge wet-lab roles on the company site remain fully in-person; the commercial, engineering, and operational roles on the board suggest Nabla Bio is extending beyond a single building as it scales partnerships with those same three pharma companies.
That split has a logic to it. Wet-lab scientists and protein engineers need to be at the bench. Business development, account management, and certain software roles can be located near pharma partners or in hiring markets where the relevant talent sits. Candidates should expect the default for scientific roles to be relocation to Cambridge, while non-lab roles may be opened in other cities or remotely within the U.S. If a posting does not specify a location, ask the recruiter directly; the answer will signal which side of the company's in-person/remote line the role falls on, and whether relocation support is on the table.
Who Thrives Here
Nabla Bio tells candidates who they want in three sentences on the team page: "We are scientists and engineers driven to make drug development a true design discipline. Our culture prizes speed, creativity, and rigor: we debate ideas with data, not ego; we value steep growth over static titles; and we work in-person, shoulder-to-shoulder in the lab every day." That passage names the three traits, spells out a behavioral norm, and quietly rules out a whole category of candidate: anyone who wants a quiet, remote-first role. Read it as a filter, not a tagline.
The Glassdoor data on the parent brand "Nabla," thin as it is, lines up directionally. Across 17 anonymous reviews, 65% of Nabla employees would recommend the company to a friend. The strongest reviews describe a "fast paced, highly collaborative atmosphere which allows employees to have an impact cross functionally and contribute to meaningful initiatives," with the word impact recurring; employees say they feel their work reaches clinicians and patients, not just internal dashboards. If you need a slow ramp-up to feel ownership, the reviews suggest Nabla is not designed for that.
What that looks like in practice: Nabla Bio's recent output is a machine-learning system called JAM-2, which the team announced in 2025 as a way to generate "drug-like antibodies straight from the computer." That kind of result depends on people who can carry a problem across disciplines, someone who writes the model, validates it against wet-lab binding data, and argues for a design choice in front of a skeptical bench scientist. The team's own posts make the point concretely: the boundary between "computational" and "experimental" is deliberately porous, and the people who do well move across it.
Two traits show up repeatedly enough to treat as predictors. First, steep growth over static titles: Nabla Bio says it out loud, and the role mix on the Zero G Talent board reinforces it. The New York posting for an SRE / Backend Engineer spans $160,000–$220,000, a 38% spread between the floor and ceiling of one requisition. That kind of band implies they pay for demonstrated range, not years-in-role. Second, comfort with in-person lab work. "Shoulder-to-shoulder" is not boilerplate; it rules out remote-only candidates and favors people who have already chosen bench-or-equivalent work as a daily practice rather than a phase.
A countervailing signal matters to name. The Glassdoor sample is small (17 reviews), and the MyVisaJobs page notes the company has not yet been reviewed by employees or job applicants on that platform. The 65% figure is directionally useful but not statistically settled. Treat the trait list above as a working hypothesis from Nabla Bio's own writing and a small employee sample, not a verified personality profile.
So who actually thrives? People who argue from data and update when the data moves; people who treat antibody design as an engineering problem worth shipping, not a research question worth publishing on; people who already work at the bench or beside it and don't need to be sold on in-person collaboration; and people who measure themselves by what they shipped this quarter, not the title on the last review. Nabla Bio asks candidates to send a CV and "evidence of why you'd be a great fit for this role" to [email protected], and the evidence they want is the kind a portfolio of problems, papers, or shipped models produces. The 840 Memorial Drive lab will only run if the people in it can stand shoulder-to-shoulder, five programs every six weeks, and argue about the next antibody until the data settles.
Working in frontier tech? Zero G Talent tracks the openings: see every open Nabla Bio role, browse frontier tech jobs, the companies hiring, and the people building the field.